Gilead Sciences, (GILD) Financials
Gilead Sciences, (GILD) Historical Financial Statements and Key Metrics for 1996 - 2026
Full Gilead Sciences, financials for 1996 - 2026 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Gilead Sciences, Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2026-Jun-30 | 7,803 | 6,224 (79.8 %) | -10,394 (-133.2 %) | -10,496 (-134.5 %) | -10,007 | -8.45 |
| 2026-Mar-31 | 6,960 | 5,515 (79.2 %) | 2,586 (37.2 %) | 2,021 (29.0 %) | 3,040 | 1.61 |
| 2025-Dec-31 | 7,925 | 6,882 (86.8 %) | 2,964 (37.4 %) | 2,183 (27.5 %) | 2,333 | 1.74 |
| 2025-Sep-30 | 7,769 | 6,200 (79.8 %) | 3,327 (42.8 %) | 3,052 (39.3 %) | 4,583 | 2.43 |
| 2025-Jun-30 | 7,081 | 5,580 (78.8 %) | 2,474 (34.9 %) | 1,960 (27.7 %) | 3,374 | 1.56 |
| 2025-Mar-31 | 6,667 | 5,127 (76.9 %) | 2,237 (33.6 %) | 1,315 (19.7 %) | 2,605 | 1.04 |
| 2024-Dec-31 | 7,569 | 5,988 (79.1 %) | 2,451 (32.4 %) | 1,783 (23.6 %) | 3,109 | 1.42 |
Full historical income statements for 1996 - 2026 is included in the
US Historical Financials dataset.
Gilead Sciences, Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2026-Jun-30 | 49,363 | 37,618 | 2,414 | 11,744 | 3,179 |
| 2026-Mar-31 | 56,278 | 32,847 | 22,174 | 23,515 | 9,817 |
| 2025-Dec-31 | 59,023 | 36,405 | 24,592 | 22,618 | 10,605 |
| 2025-Sep-30 | 58,533 | 37,077 | 24,941 | 21,540 | 7,349 |
| 2025-Jun-30 | 55,721 | 36,130 | 24,946 | 19,675 | 5,213 |
| 2025-Mar-31 | 56,434 | 37,356 | 24,952 | 19,162 | 7,926 |
| 2024-Dec-31 | 58,995 | 39,749 | 26,711 | 19,330 | 9,991 |
Full historical balance sheet data for 1996 - 2026 is included in the
US Historical Financials dataset.
Gilead Sciences, Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2026-Jun-30 | 3,573 | -10,347 | 2,344 | 3,690 |
| 2026-Mar-31 | 2,544 | 1,770 | -4,239 | 2,427 |
| 2025-Dec-31 | 3,326 | -1,835 | -1,263 | 3,121 |
| 2025-Sep-30 | 4,108 | -427 | -1,489 | 3,961 |
| 2025-Jun-30 | 827 | -2,116 | -1,567 | 720 |
| 2025-Mar-31 | 1,757 | -415 | -3,426 | 1,653 |
| 2024-Dec-31 | 2,975 | -225 | 2,260 | 2,975 |
Full historical cash flow data for 1996 - 2026 is included in the
US Historical Financials dataset.
Gilead Sciences, Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2026-Jun-30 | 157,041 | 156,276 | 20.13 | -3.74 | 13.37 |
| 2026-Mar-31 | 173,098 | 187,644 | 24.87 | 21.41 | 7.36 |
| 2025-Dec-31 | 152,443 | 169,471 | 19.24 | 17.46 | 6.74 |
| 2025-Sep-30 | 137,973 | 155,584 | 17.76 | 11.30 | 6.41 |
| 2025-Jun-30 | 138,033 | 157,835 | 19.49 | 17.61 | 7.02 |
| 2025-Mar-31 | 139,614 | 156,640 | 20.94 | 26.54 | 7.29 |
| 2024-Dec-31 | 115,278 | 131,998 | 15.23 | 16.16 | 5.96 |
Full historical valuation and operating metrics for 1996 - 2026 are included in the
US Historical Financials dataset.